|Articles|July 28, 2016
Oncology-Focused Biotech Selects Medidata
Start-up biotech selects Medidata Rave for Phase I and II trials of its investigational compound to address solid tumors and blood cancers.
Advertisement
Forty Seven Inc., a Stanford University start-up biotech specializing in cancer immunotherapy, will use Medidata’s electronic data capture, management and reporting system Medidata Rave in two of its upcoming Phase I and Phase II trials. Forty Seven takes its name from CD47 tumor cell protein that its lead molecule, Hu5F9-G4-an experimental monoclonal cancer drug-to be tested in solid tumor and blood cancers.
Read the full release .
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
- How Sponsors Can Modernize Tools to Support Physicians
September 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
2
Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC
3
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
4
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
5